These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9694740)

  • 1. Is hydroxyurea leukemogenic in essential thrombocythemia?
    Tefferi A
    Blood; 1998 Aug; 92(4):1459-60; author reply 1460-1. PubMed ID: 9694740
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacious treatment of a fatal blood disease: polycythemia vera].
    Sánchez Fayos J; Román Barbero A; Nevado Reviriego I
    Sangre (Barc); 1997 Jun; 42(3):215-8. PubMed ID: 9381264
    [No Abstract]   [Full Text] [Related]  

  • 4. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
    Passamonti F; Lazzarino M
    Leuk Lymphoma; 2003 Sep; 44(9):1483-8. PubMed ID: 14565648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.
    Sterkers Y; Preudhomme C; Laï JL; Demory JL; Caulier MT; Wattel E; Bordessoule D; Bauters F; Fenaux P
    Blood; 1998 Jan; 91(2):616-22. PubMed ID: 9427717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET).
    Brodsky I
    Am J Clin Oncol; 1998 Feb; 21(1):105-6. PubMed ID: 9499248
    [No Abstract]   [Full Text] [Related]  

  • 9. Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
    Sironi M; Bertola G; Lodato A; Spinelli M; Sciariada L
    Acta Haematol; 2003; 109(3):161-2. PubMed ID: 12714827
    [No Abstract]   [Full Text] [Related]  

  • 10. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
    Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Brusamolino E; Passamonti F; Volpe G; Pistorio A; Giardini I; Rocca B; Caresana M; Lazzarino M; Bernasconi C
    Leukemia; 2002 Oct; 16(10):2078-83. PubMed ID: 12357360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment paradigms in the management of myeloproliferative disorders.
    Fruchtman SM
    Semin Hematol; 2004 Apr; 41(2 Suppl 3):18-22. PubMed ID: 15190519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
    Michiels JJ; Pich A; De Raeve H; Gadisseur A
    Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
    [No Abstract]   [Full Text] [Related]  

  • 14. Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
    Dingli D; Tefferi A
    Curr Hematol Malig Rep; 2006 Jun; 1(2):69-74. PubMed ID: 20425334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
    Najean Y; Rain JD; Dresch C; Goguel A; Lejeune F; Echard M; Grange MJ
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():111-9. PubMed ID: 8951781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
    Sever M; Newberry KJ; Verstovsek S
    Leuk Lymphoma; 2014 Dec; 55(12):2685-90. PubMed ID: 24524340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17.
    Tóthová E; Fricová M; Stecová N; Hlebasková M; Kafková A; Raffac S; Guman T; Svorcová E; Nebesnáková E
    Neoplasma; 2001; 48(5):389-92. PubMed ID: 11845984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
    Barbui T
    Semin Hematol; 2004 Apr; 41(2 Suppl 3):15-7. PubMed ID: 15190518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The management of elderly patients with myeloproliferative disorders.
    Tura S
    Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.